Hibercell’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Hibercell develops and commercializes novel therapeutics for the treatment of tumors and metastatic cancer. Read more

1 Followers on Owler
1 Followers on Owler
1 Followers on Owler
1 Followers on Owler

Hibercell develops and commercializes novel therapeutics for the treatment of tumors and metastatic cancer. Read more

Alan Rigby's photo - Co-Founder & CEO of Hibercell

Co-Founder & CEO

Alan Rigby

CEO Approval Rating

85/100

Founded:

2018

Status:

PrivateIndependent Company

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Allogene is Hibercell's top competitor. Allogene is a Public company that was founded in South San Francisco, California in 2017. Allogene operates in the Pharmaceuticals industry. Allogene has 233 more employees vs. Hibercell.

StemTek Therapeutics has been one of Hibercell's top competitors. StemTek Therapeutics is headquartered in Derio, Basque Country, and was founded in 2013. StemTek Therapeutics is in the Biotechnology field. StemTek Therapeutics generates 350% the revenue of Hibercell.

Transcode Therapeutics is perceived as one of Hibercell's biggest rivals. Transcode Therapeutics was founded in 2016 in Boston, Massachusetts. Transcode Therapeutics competes in the Biotechnology field. Transcode Therapeutics generates $500K more revenue than Hibercell.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 3 a good estimate for Hibercell's Employee count?

Acquisitions

No recent acquisitions found related to Hibercell

Hibercell Funding History

$60.8M

Since Hibercell was founded in 2018, it has participated in 1 round of funding. In total Hibercell has raised $60.8M. Hibercell's funding round was on Feb 2019 for a total of $60.8M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series A
Feb 2019
$60.8M

ARCH Venture Partners

Since Hibercell was founded in 2018, it has participated in 1 round of funding. In total Hibercell has raised $60.8M. Hibercell's funding round was on Feb 2019 for a total of $60.8M

Investments

No recent investments found related to Hibercell

Hibercell News

February 8, 2019BioPortfolio

HiberCell Raises $61 Million to Target Cancer Metastases; Hillhouse and 6 Dimensions Participate

HiberCell a New York City biotech startup started operations with $60.75 million in Series A funding ... See more »
February 7, 2019MedCity News

Startup HiberCell gets more than $60M to focus on mechanism behind cancer metastasis, recurrence

The New York-based company has two programs in preclinical discovery, based on research conducted at ... See more »

Hibercell Press Releases

Social Media

Headquarters

619 West 54th Street, 8th Floor

New York, New York10019

212-601-2800

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Hibercell develops and commercializes novel therapeutics for the treatment of tumors and metastatic cancer. Hibercell was founded in 2018. Hibercell's headquarters is located in New York, New York, USA 10019. It has raised 60.8M in 1 round. The latest...

CEO

Hibercell's Co-Founder & CEO, Alan Rigby, currently has an approval rating of 85%. Hibercell's primary competitors are Allogene, StemTek Therapeutics & Transcode Therapeutics.

Website

HiberCell.com

Frequently Asked Questions about Hibercell

  1. When was Hibercell founded?

    Hibercell was founded in 2018
  2. Who is Hibercell's CEO?

    Hibercell's CEO is Alan Rigby
  3. How much revenue does Hibercell generate?

    Hibercell generates $ < 1M in revenue
  4. How much funding does Hibercell have?

    Hibercell has historically raised $60.8M in funding
  1. Where is Hibercell's headquarters?

    Hibercell's headquarters is in New York New York, USA
  2. How many employees does Hibercell have?

    Hibercell has 3 employees
  3. What sector does Hibercell operate in?

    Hibercell is in Biotechnology
  4. Who are Hibercell's competitors?

    Hibercell's top competitors are Allogene, StemTek Therapeutics, Transcode Therapeutics